Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 10Phase 4 5Phase 2/3 3Phase 1 3Phase NA 2Phase 1/2 2

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × luprolide acetate gel depot × Genitourinary × Clear all
NCT06305598 2026-05-15

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
14 enrolled
Genitourinary

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT01642732 2017-05-30

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

University of Michigan Rogel Cancer Center

Phase 1 Terminated
1 enrolled 2 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡